{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:26:41Z","timestamp":1783553201487,"version":"3.55.0"},"reference-count":67,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>With any new disease a framework for the development of preventative or treatment therapeutics is key; the absence of such in COVID\u201019 has enabled ineffective and potentially unsafe treatments to be taken up by governments and clinicians desperate to have options for patients. As we still have few therapies and nil vaccines yet available, the void of a clear framework for research and practice is increasingly clear. We describe a framework that has been used to prioritise therapeutic research in previous pandemics which could be used to progress clinical pharmacology and therapeutics research in COVID\u201019.<\/jats:p><jats:p>This is particularly relevant as discussion has already moved on from antiviral therapeutics to delineating the treatment of the host from treatment and elimination of the infective agent. Focussing on the host brings together three concepts: host treatment, the damage response framework and therapeutic repurposing. The integration of these three areas plays to the traditional strength of pharmaceuticals in providing a period of stabilization to permit time for the development of novel antiviral drugs and vaccines. In integrating approaches to repurposing, host treatment and damage response we identified three key properties that a potentially effective repurposed drug must possess by way of a framework. There must be homology, i.e., the same or similar relation with the pathogenesis of the disease, ideally targeted to the conserved pathophysiological outcomes of the viral attack; there must be a defined locus within the spectrum to prevention to severe disease and the framework must draw upon the historical dose and safety experience of the repurposed drug. To illustrate, we have mapped therapeutics that impact upon a key dysregulated pathway in COVID\u201019 \u2013 the renin angiotensin system \u2013 using this approach. Collectively this type of analysis reveals the importance of existing data (repurposed information and administrative observational data) and the importance of the details of the known pathophysiological response to viruses in approaches to treating the host.<\/jats:p>","DOI":"10.1111\/bcp.14551","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T11:41:58Z","timestamp":1600774918000},"page":"875-885","source":"Crossref","is-referenced-by-count":9,"title":["A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID\u201019"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-0199","authenticated-orcid":false,"given":"Jennifer H.","family":"Martin","sequence":"first","affiliation":[{"name":"Centre for Human Drug Repurposing and Medicines Research University of Newcastle NSW 2305 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-0926","authenticated-orcid":false,"given":"Richard","family":"Head","sequence":"additional","affiliation":[{"name":"University of South Australia South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"issue":"18","key":"e_1_2_7_2_1","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID\u201019): a review","volume":"323","author":"Sanders JM","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00716-15"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.11.03"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/jeccm.2017.05.03"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00398-20"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-015-4814-7"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50603"},{"issue":"4","key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"e00620","DOI":"10.1002\/prp2.620","article-title":"Buying time: drug repurposing to treat the host in COVID\u201019H","volume":"00","author":"Martin JH","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"e_1_2_7_10_1","first-page":"1","article-title":"Dexamethasone in hospitalized patients with Covid\u201019 \u2014 preliminary report","author":"The RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy083"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.168"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.06.015"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa097"},{"key":"e_1_2_7_16_1","first-page":"m406","article-title":"Response to the emerging novel coronavirus outbreak","volume":"368","author":"Brandon MH","year":"2020","journal-title":"BMJ"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2007.040048"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.04.037"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0455-8"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00217.2020"},{"key":"e_1_2_7_22_1","article-title":"Exosome\u2010mediated transfer of ACE2 (angiotensin\u2010converting enzyme 2) from endothelial progenitor cells promotes survival and function of endothelial cell","volume":"2020","author":"Wang J","journal-title":"Oxid Med Cell Longev"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709739105"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005014"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvr214"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2018.15"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.05.003"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30121-1"},{"issue":"7","key":"e_1_2_7_29_1","first-page":"389","article-title":"COVID\u201019: the vasculature unleashed nature reviews","volume":"20","author":"Teuwen L\u2010A","year":"2020","journal-title":"Immunology"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0327-4"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02638-2017"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037059209077670"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1851OC"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","unstructured":"JeffresonS RushR ZettlerC FrewinDB HeadRJ.The influence of the renin angiotensin system on abnormal expression of nerve growth factor in the spontaneously hypertensive rat.July 1995;22(6\u20107):478\u2010480.https:\/\/doi.org\/10.1111\/j.1440-1681.1995.tb02050.x","DOI":"10.1111\/j.1440-1681.1995.tb02050.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00628-1"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02344-6"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02274-10"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16472"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00439"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00479.2015"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200600459"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0063fje"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317134"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007621"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746200"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa447"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.314558"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001524"},{"key":"e_1_2_7_50_1","article-title":"ACE\u2010inhibitors and Angiotensin\u20102 receptor blockers are not associated with severe SARS\u2010 COVID\u201019 infection in a multi\u2010site UK acute hospital trust","author":"Bean D","journal-title":"medRxiv"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis733"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003654"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001382"},{"key":"e_1_2_7_54_1","article-title":"Association of angiotensin\u2010converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease\u201019","author":"Khera R","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31030-8"},{"key":"e_1_2_7_56_1","article-title":"Renin\u2010angiotensin\u2010aldosterone system inhibitors and COVID\u201019 infection or hospitalization: a cohort study. Preprint","author":"Dublin S","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.163576"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2016.35"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15082"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2108086"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.4266\/kjccm.2016.00976"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.061945"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-015-0044-3"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.494597"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)82002-5"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4984"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050067"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2018.1499293"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T18:16:22Z","timestamp":1696702582000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/bcp.14551"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14551","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]}}}